Grants, Honors, Awards & Recognitions Archive

Scot Wolfe, PhD, and collaborator Charles Emerson, Jr., PhD, (professor of neurology and Director of the Wellstone Muscular Dystrophy Program at UMass Chan) have received a three-year grant from the Muscular Dystrophy Association to develop a precise genome editing therapy to correct a common mutation in the TCAP gene, which leads to the R7 subtype of limb girdle muscular dystrophy. The project, which combines the use of stem cell, nanoparticle, mouse model and genome editing technologies, will provide a versatile platform to develop correction therapies for other gene mutations that cause other types of muscular dystrophy.

Andreas Bergmann, PhD, has been featured by the UMass Cancer Walk ahead of the annual event. Learn more about how Dr. Bergmann got into the field of cancer research, and his thoughts on what makes UMass Chan a special place to do research.

Read the full story on the UMass Cancer Walk website.

Marcus Ruscetti, PhD, and collaborator (and MCCB adjunct faculty) Prabhani Atukorale, PhD, have been featured in a news spotlight by NBC10 Boston to showcase their ground-breaking combination immunotherapy approach that dramatically reduces pancreatic tumors in mice.

Watch the video from NBC10 Boston, and read the related story from UMass Chan News.

Yong-Xu Wang, PhD, has received NIH funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to investigate a new approach for resolution of nonalcoholic fatty liver and nonalcoholic steatohepatitis by a novel adipokine. Nonalcoholic steatohepatitis (NASH) is a type of liver disease caused by the accumulation of fat in the organ, and can lead to cirrhosis, liver failure and cancer. The grant will determine whether an adipose-enriched cytokine identified by Dr. Wang’s group can improve NASH symptoms in mouse models of the disease, and will investigate the cytokine’s mechanism-of-action.

Leslie Shaw, PhD, has received NIH funding from the National Cancer Institute (NCI) to investigate the role of IRS2 and mitotic regulation in breast cancer. The grant will explore the mechanism by which IRS2, a signaling adaptor protein, regulates chromosome segregation during cell division, and evaluate the feasibility of targeting IRS2 as a therapeutic strategy for the treatment of triple negative breast cancer, an aggressive type of breast cancer.

Will Flavahan, PhD, has received an NIH Director’s New Innovator Award, an initiative designed to support exceptionally creative early stage investigators who propose highly innovative research projects with the potential to impact areas important to NIH’s mission. Dr. Flavahan proposes to build upon a technique developed in his lab to generate comprehensive “training libraries” of DNA and RNA modifications that will expand the capabilities of third-generation sequencing for multi-dimensional genome and transcriptome analysis. The results of the project will provide tools for better understanding how nucleic acids are damaged during aging or cancer treatment.

Read the full story from UMass Chan News.